Fig. 1



BxPC3
SC
(5x10⁶/100 µL)
SCID mice
SPLIT BsAb VH+VL
212Pb-DOTAM (20 µCi)
BD (n=3)
d14
d21
d22
d28
d35
d36
d42
d49
d50
A n=19
B n=19
C n=19
D n=19
E n=3
Vehicle (200 µL IP or 100 µL IV)
212Pb-DOTAM (20 µCi) (IV)
P1AI0084 (5 mg/kg) + P1AI0446 (5 mg/kg) (IP)
P1AI1622 (5 mg/kg) + P1AI0034 (5 mg/kg) (IP)
P1AJ6062 (5 mg/kg) + P1AJ6059 (5 mg/kg) (IP)
P1AJ6063 (5 mg/kg) + P1AJ6064 (5 mg/kg) (IP)

Fig. 2



%IA/g ± SD (n=3)
40
30
20
10
0
P1AI0084 + P1AI0446 (cycle 1)
P1AI0084 + P1AI0446 (cycle 2)
P1AI0084 + P1AI0446 (cycle 3)
P1AI1622 + P1AI0034 (cycle 1)
P1AI1622 + P1AI0034 (cycle 2)
P1AI1622 + P1AI0034 (cycle 3)
P1AJ6062 + P1AJ6059 (cycle 1)
P1AJ6062 + P1AJ6059 (cycle 2)
P1AJ6062 + P1AJ6059 (cycle 3)
P1AJ6063 + P1AJ6064 (cycle 1) (n=5)
Blood
Spleen
Pancreas
Kidneys
Liver
Muscle
Tail
Tumor

Fig. 3



Tumor volume ± SD (mm3)
2500
2000
1500
1000
500
0
0
50
100
150
Days after cell injection
Dotted line = 212Pb-DOTAM
Vehicle
P1AI0084 + P1AI0446
P1AI1622 + P1AI0034
P1AJ6062 + P1AJ6059
(n=10)
Curves truncated at n<5

Fig. 4



Vehicle (n=10)
P1AI0084 + P1AI0446 (n=10)
P1AI1622 + P1AI0034 (n=10)
P1AJ6062 + P1AJ6059 (n=10)
Tumor volume (mm3)
Days after cell injection
0
1000
2000
3000
50
100
150
200

Fig. 5



Probability of Survival
100
50
0
0
20
40
60
80
100
120
140
160
Days after cell injection
Vehicle
P1AI0084 + P1AI0446
P1AI1622 + P1AI0034
P1AJ6062 + P1AJ6059

Fig. 6



120
110
100
90
80
70
60
Body weight ± SD (%)
0
50
100
150
Days after cell injection
Dotted line = 212Pb-DOTAM
Vehicle
P1AI0084 + P1AI0446
P1AI1622 + P1AI0034
P1AJ6062 + P1AJ6059
(n=10)
Curves truncated at n<5

Fig. 7



BxPC3
SC
(5×10⁶/100 µL)
SCID mice
SPLIT BsAb VH+VL
212Pb-DOTAM (20 µCi)
BD (n=3)
d14
d21
d22
d28
d35
d36
d42
d49
d50
A n=19
B n=19
Vehicle (200 µL IP or 100 µL IV)
212Pb-DOTAM (20 µCi) (IV)
P1AJ6063 (5 mg/kg) + P1AJ6064 (5 mg/kg) (IP)

Fig. 8



40
30
20
10
0
%IA/g ± SD (n=3)
P1AI6063 + P1AJ6064 (cycle 1)
P1AI6063 + P1AJ6064 (cycle 2)
P1AI6063 + P1AJ6064 (cycle 3)
Blood
Spleen
Pancreas
Kidneys
Liver
Muscle
Tail
Tumor

Fig. 9



Tumor volume ± SD (mm3)
2000
1500
1000
500
0
0
50
100
150
Days after cell injection
Dotted line = 212Pb-DOTAM
Vehicle
P1AI6063 + P1AJ6064
(n=10)
Curves truncated at n<5

Fig. 10



P1AJ6063 + P1AJ6064 (n=10)
Tumor volume (mm³)
3000
2000
1000
0
0
50
100
150
Days after cell injection
Vehicle (n=10)
Tumor volume (mm³)
3000
2000
1000
0
0
50
100
150
Days after cell injection

Fig. 11



Probability of Survival
100
50
0
0
20
40
60
80
100
120
140
160
Days after cell injection
Vehicle
P1AI6063 + P1AJ6064

Fig. 12





120
110
100
90
80
70
60
Body weight ± SD (%)
0
50
100
150
Days after cell injection
Dotted line =
212Pb-DOTAM
Vehicle
P1AI6063 + P1AJ6064
(n=10)
Curves
truncated
at n<5

Fig. 13A



Target Binder	Effector		Protein	LC	HC	FusionHC
CH1A1A	Dotam	VL	P1AI0446	D1AD3421	D1AC4023	D1AK6882
		VH	P1AI0084	D1AD3421	D1AC4022	D1AK7032
T84.66v	Dotam	VL	P1AJ6059	D1AM8341	D1AS9437	D1AS9439
		VH	P1AJ6062	D1AM8341	D1AN8651	D1AS9435

Fig. 13B



Target Binder	Effector		Protein	LC	HC-VH	HC-VL
CH1A1A	Dotam	VL	P1AI0034	D1AD3421	D1AK6974	D1AK6882
		VH	P1AI1622	D1AD3421	D1AH1088	D1AK6959
T84.66v	Dotam	VL	P1AJ6063	D1AM8341	D1AS9441	D1AS9439
		VH	P1AJ6064	D1AM8341	D1AS9447	D1AS9449